Working in silos, change will not occur. WBC convenes with our Partners, Champions, and Sponsors to move faster together toward our action initiative goals.
Join us for Our Annual Action for Impact Summit!
WBC’s Annual Action for Impact Summit unites thousands of attendees on a fully interactive platform, enabling participants to network, connect, and exchange ideas, innovations, and impact in real time.
WOMEN CEO REPORT
Jodie is CEO of Q32 Bio and was previously a venture partner and CEO of Cadent Therapeutics until its sale to Novartis in 2020. Previously she served as interim CEO at Keryx Biopharmaceuticals (managed Akebia merger), COO at Syntimmune (acquired by Alexion), and CEO of Tokai Pharmaceuticals (led 2014 IPO). Before her tenure in executive leadership, she held positions in clinical and medical affairs at companies including Dyax, Curis, and Diacrin. Jodie received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. in neuroscience from Mount Holyoke College. Jodie has been awarded the Boston Business Journals Power 50 and Women to Watch awards and WESTs Making a Difference awar
